Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections
European Journal of Clinical Microbiology & Infectious Diseases · 2023
DOI: 10.1007/s10096-023-04572-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2023. Verfasst von Sebastián Marciano und 47 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. sebastian.marciano@hospitalitaliano.org.ar. Hauptthemen laut MEDLINE: Bacterial Infections, Peritonitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
It is unclear whether norfloxacin predisposes to infections by multidrug-resistant organisms (MDROs). We aimed to evaluate if patients with cirrhosis receiving norfloxacin prophylaxis at the time of the diagnosis of bacterial infections were more likely to present a multidrug-resistant isolate than those without prophylaxis. This is a cross-sectional study of hospitalized patients with cirrhosis and bacterial infections from Argentina and Uruguay (NCT03919032) from September 2018 to December 2020. The outcome variable was a multidrug-resistant bacterial infection. We used inverse probability of treatment weighting to estimate the odds ratio (OR) of norfloxacin on infection caused by MDROs considering potential confounders. Among the 472 patients from 28 centers, 53 (11%) were receiving norfloxacin at the time of the bacterial infection. Patients receiving norfloxacin had higher MELD-sodium, were more likely to have ascites or encephalopathy, to receive rifaximin, beta-blockers, and proton-pump inhibitors, to have a nosocomial or health-care-associated infection, prior bacterial infections, admissions to critical care units or invasive procedures, and to be admitted in a liver transplant center. In addition, we found that 13 (24.5%) patients with norfloxacin and 90 (21.5%) of those not receiving it presented infections caused by MDROs (adjusted OR 1.55; 95% CI: 0.60-4.03; p = 0.360). The use of norfloxacin prophylaxis at the time of the diagnosis of bacterial infections was not associated with multidrug resistance. These results help empiric antibiotic selection and reassure the current indication of norfloxacin prophylaxis in well-selected patients.Study registration number: NCT03919032.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. sebastian.marciano@hospitalitaliano.org.ar.
- Department of Research, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. sebastian.marciano@hospitalitaliano.org.ar.
- P. R. Liver Unit, Hospital 4 de Junio, Sáenz Peña, Argentina.
- Liver Unit, Hospital Churruca Visca, Buenos Aires, Argentina.
- Liver Unit, Sanatorio Güemes, Buenos Aires, Argentina.
- Liver Unit, Hospital Alemán, Buenos Aires, Argentina.
Zitieren
APA
Marciano, S., Gutierrez-Acevedo, M. N., Barbero, S., Del C Notari, L., Agozino, M., Fernandez, J. L., Anders, M. M., Grigera, N., Antinucci, F., Orozco Ganem, O. F., Murga, M. D., Perez, D., Palazzo, A., Martinez Rejtman, L., Duarte, I. G., Vorobioff, J., Trevizan, V., Bulaty, S., Bessone, F., …, & Giunta, D. H. (2023). Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-023-04572-2
Vancouver
Marciano S, Gutierrez-Acevedo MN, Barbero S, Del C Notari L, Agozino M, Fernandez JL, et al. Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections. European Journal of Clinical Microbiology & Infectious Diseases. 2023. doi:10.1007/s10096-023-04572-2
BibTeX
@article{Marciano2023,
author = {Marciano, Sebastián and Gutierrez-Acevedo, Maria N and Barbero, Sabrina and Del C Notari, Lorena and Agozino, Marina and Fernandez, Jose L and Anders, Maria M and Grigera, Nadia and Antinucci, Florencia and Orozco Ganem, Orlando F and Murga, Maria D and Perez, Daniela and Palazzo, Ana and Martinez Rejtman, Liria and Duarte, Ivonne G and Vorobioff, Julio and Trevizan, Victoria and Bulaty, Sofía and Bessone, Fernando and Valverde, Marcelo and Elizondo, Martín and Bosia, José D and Borzi, Silvia M and Stieben, Teodoro E and Masola, Adriano and Ferretti, Sebastian E and Arufe, Diego and Demirdjian, Ezequiel and Raffa, Maria P and Peralta, Mirta and Fainboim, Hugo A and Vazquez, Cintia E and Ruiz, Pablo and Martínez, José E and Heffner, Leandro A and Odzak, Andrea and Dirchwolf, Melisa and Smud, Astrid and Mendizabal, Manuel and Bellizzi, Carla and Martinez, Ana and Tomatis, Jesica and Bruno, Andres and Ramos, Agñel and Pages, Josefina and Tevez, Silvina and Gadano, Adrian C and Giunta, Diego H},
title = {Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2023},
doi = {10.1007/s10096-023-04572-2}
}
EUVIMED